A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment

Kidney International

Volumn 87, Issue 1, 2015, Pages 225-232

  Yoshikawa, Norishige ^a   Nakanishi, Koichi ^a   Sako, Mayumi ^b   Oba, Mari S ^c   Mori, Rintaro ^b   Ota, Erika ^b   Ishikura, Kenji ^d   Hataya, Hiroshi ^d   Honda, Masataka ^d   Ito, Shuichi ^b   Shima, Yuko ^a   Kaito, Hiroshi ^e   Nozu, Kandai ^e   Nakamura, Hidefumi ^b   Igarashi, Takashi ^b   Ohashi, Yasuo ^f   Iijima, Kazumoto ^e  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

^d TOKYO METROPOLITAN CHILDREN'S MEDICAL CENTER   (Japan)

^e KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

Author keywords

Initial treatment; nephrotic syndrome; pediatric nephrology; randomized controlled trial; steroid

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; PREDNISOLONE; GLUCOCORTICOID;

ACUTE KIDNEY FAILURE; ADRENAL INSUFFICIENCY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CATARACT; CHILD; CONTROLLED STUDY; CUSHINGOID SYNDROME; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; FEMALE; FOLLOW UP; GLAUCOMA; HAZARD RATIO; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTIC SYNDROME; OBESITY; ONSET AGE; OPEN STUDY; PEPTIC ULCER; PNEUMONIA; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK ASSESSMENT; STRIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADOLESCENT; CLINICAL TRIAL; COMPARATIVE STUDY; INFANT;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GLUCOCORTICOIDS; HUMANS; INFANT; MALE; NEPHROTIC SYNDROME; PREDNISOLONE; RECURRENCE;

EID: 84920114535     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.260     Document Type: Article

References (20)

1. Schlesinger ER, Sultz HA, Mosher WE et al. The nephrotic syndrome: its incidence and implications for The community. Am J Dis Child 1968; 116: 623-632.
2. van Husen M, Kemper MJ. New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol 2011; 26: 881-892.
3. Tarshish P, Tobin JN, Bernstein J et al. Prognostic significance of The early course of minimal change nephrotic syndrome: report of The International Study of Kidney Disease in Children. J Am Soc Nephrol 1997; 8: 769-776.
4. Ueda N, Chihara M, Kawaguchi S et al. Intermittent versus long-term tapering prednisolone for initial therapy in children with idiopathic nephrotic syndrome. J Pediatr 1988; 112: 122-126.
5. Ehrich JH, Brodehl J. Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie. Eur J Pediatr 1993; 152: 357-361.
6. Ksiazek J, Wyszyńska T. Short versus long initial prednisone treatment in steroid-sensitive nephrotic syndrome in children. Acta Paediatr 1995; 84: 889-893.
7. Bagga A, Hari P, Srivastava RN. Prolonged versus standard prednisolone therapy for initial episode of nephrotic syndrome. Pediatr Nephrol 1999; 13: 824-827.
8. Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 2010; 4: CD001533.
9. Hodson EM, Alexander SI. Evaluation and management of steroid-sensitive nephrotic syndrome. Curr Opin Pediatr 2008; 20: 145-150.
10. Hodson EM, Craig JC, Willis NS. Evidence-based management of steroid-sensitive nephrotic syndrome. Pediatr Nephrol 2005; 20: 1523-1530.
11. Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst Rev 2008; 23: CD002290.
12. MacHardy N, Miles PV, Massengill SF et al. Management patterns of childhood-onset nephrotic syndrome. Pediatr Nephrol 2009; 24: 2193-2201.
13. Teeninga N, Kist-van Holthe J, van Rijskwijk N et al. Extending prednisolone therapy does not reduce relapse in childhood nephrotic syndrome. J Am Soc Nephrol 2013; 24: 149-159.
14. Hodson EM, Craig JC. Corticosteroid therapy for steroid-sensitive nephrotic syndrome in children: dose or duration? J Am Soc Nephrol 2013; 24: 7-9.
15. Iijima K, Sako M, Oba MS et al. Japanese Study Group of Kidney Disease in Children. Cyclosporine C2 monitoring for The treatment of frequently relapsing nephrotic syndrome in children: a multicenter randomized phase II trial. Clin J Am Soc Nephrol 2014; 9: 271-278.
16. Kobayashi T, Saji T, Otani T et al. RAISE study group investigators. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012; 379: 1613-1620.
17. Nakanishi K, Iijima K, Ishikura K et al. Two-year outcome of The ISKDC regimen and frequent-relapsing risk in children with idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 2013; 8: 756-762.
18. Mishra OP, Thakur N, Mishra RN et al. Prolonged versus standard prednisolone therapy for initial episode of idiopathic nephrotic syndrome. J Nephrol 2012; 25: 394-400.
19. Hiraoka M, Tsukahara H, Matsubara K et al. A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children. Am J Kidney Dis 2003; 4: 1155-1162.
20. Yoshikawa N, Ito H, Takehoshi Y et al. Standard versus long-term prednisolone with Sairei-to in childhood steroid-responsive nephrotic syndrome: a prospective controlled study. Jpn J Nephrol 1998; 40: 587-590.